The knowledge and perception of factor concentrate in persons with haemophilia A

EDNA P. BOLIVAR, RINAH I. SHOPNICK, PIER M. MANNUCCI, ALESSANDRO GRINGERI, DOREEN B. BRETTLER

Research output: Contribution to journalArticlepeer-review

Abstract

Summary. Objectiues. To evaluate haemophilia patients' knowledge and understanding of factor concentrate products and to assess their feelings regarding purity and viral safety of these products. Methods. Sixty questionnaires were distributed and completed by patients or parents of patients with severe/ moderate haemophilia A at two large comprehensive haemophilia centres in the USA and Italy. Results. Most patients knew what brand of factor concentrate they used, but less than half were aware of how their concentrate was virally inactivated. The majority of responders perceived recombinant factor VlII as being the concentrate with the highest degree of purity. The majority felt the decision of which concentrate to use should be the care‐givers not the patients. Conclusions. It appears that patients need more education concerning the concentrate they are using, and its method of viral inactivation and purity.

Original languageEnglish
Pages (from-to)232-235
Number of pages4
JournalHaemophilia
Volume1
Issue number4
DOIs
Publication statusPublished - 1995

Keywords

  • cost.
  • factor concentrate
  • haemophilia
  • purity
  • safety

ASJC Scopus subject areas

  • Genetics(clinical)
  • Hematology

Fingerprint Dive into the research topics of 'The knowledge and perception of factor concentrate in persons with haemophilia A'. Together they form a unique fingerprint.

Cite this